Cardiac Microcatheter Market Research Report and Outlook by 2028

The cardiac microcatheter market was valued at approximately US$ 332.97 million in 2022 and is anticipated to grow to around US$ 487.20 million by 2028, reflecting a compound annual growth rate (CAGR) of 6.8% from 2023 to 2028.

The rise in the incidence of cardiovascular diseases, coupled with the increasing adoption of percutaneous coronary intervention (PCI) for managing chronic total occlusions (CTO), is driving the expansion of the cardiac microcatheter market.

A microcatheter is a slender catheter designed for use in minimally invasive medical procedures, facilitating the delivery of various devices. Its compact size allows it to navigate the intricate vascular structures within the human body effectively. Microcatheters serve multiple purposes, including providing guidewire support, facilitating exchanges, accessing distal anatomy, crossing lesions, delivering therapeutic embolics, injecting contrast media, and conducting other complex endovascular procedures. They are particularly prevalent in the context of percutaneous coronary interventions (PCI).

Increasing Adoption of PCI for Chronic Total Occlusions (CTO), Rising Healthcare Investments, and Government Initiatives

Percutaneous coronary intervention (PCI) is recognized as one of the more challenging procedures for addressing chronic total occlusions (CTO), which are characterized by the complete or near-complete blockage of one or more coronary arteries. These blockages typically persist for about three months due to plaque accumulation. According to the National Heart, Lung, and Blood Institute, CTOs are present in roughly one-third of patients undergoing angiography. In 2020, Eurostat reported that there were 1 million transluminal coronary angioplasty procedures and 138,000 cardiac bypass surgeries performed.

Over the last decade, significant advancements have been made in this field, marked by the introduction of innovative products and regulatory approvals. Nevertheless, the ongoing development of new technical devices and strategic enhancements continues to be crucial in addressing CTOs, with microcatheters playing a vital role as interventional tools. These devices offer therapeutic solutions for complex coronary interventions, including bifurcation lesions, tortuous anatomy, ostial locations, coronary calcification, angled takeoffs, and CTOs. For instance, Terumo's FineCross MG microcatheter is designed to provide guidewire support and crossability for challenging cases, including tortuous vessels and severely stenosed or calcified lesions. Furthermore, dual lumen microcatheters (DLMCs) have become essential in PCI for CTO treatment, allowing for the management of bifurcated coronary branches and enabling various techniques such as collateral selection and retrograde negotiation of the distal CTO cap. Consequently, the increasing utilization of PCIs for CTO treatment is significantly propelling the growth of the cardiac microcatheter market.

In Europe, public healthcare spending has outpaced domestic spending, particularly in high-income nations. Eurostat reported that the total government expenditure on healthcare in the EU reached approximately US$ 1,283.98 billion (or ? 1,179 billion) in 2021, accounting for 8.1% of the region's GDP. Germany led the EU in healthcare spending, with US$ 530.60 billion (? 432 billion) in 2020, followed by France at US$ 345.14 billion (? 281 billion), Italy at US$ 196.52 billion (? 160 billion), and Spain at US$ 147.39 billion (? 120 billion). Additionally, initiatives such as the European Commission's EU4Health program, the Next Generation Recovery Funds, and Horizon Europe Research Funds aim to tackle the burden of cardiovascular diseases and enhance cardiovascular health through preventive measures outlined in an EU Action Plan. This plan encompasses the entire patient journey, from prevention and early detection to treatment access and quality of life, emphasizing the importance of digitization and innovation. The rising healthcare expenditures in both developed and developing nations are expected to create significant opportunities for the cardiac microcatheter market.

The HEARTS initiative in the Americas, spearheaded by health ministries and supported by local stakeholders and the Pan American Health Organization (PAHO), is being implemented in over 1,400 health centers across 22 countries. By 2025, HEARTS aims to establish a model for managing cardiovascular risk factors such as hypertension, diabetes, and dyslipidemia in primary healthcare settings throughout the Americas. Furthermore, heart disease incurs an estimated cost of US$ 46.3 billion in the Asia Pacific region, which includes Australia, Mainland China, Hong Kong, Japan, Singapore, South Korea, Taiwan, and Thailand. A 2022 study published in PLOS One calculated the average cost of treating cardiovascular diseases at US$ 3,842 (INR 247,822) per patient, with rheumatic heart disease being the most expensive to treat, followed by cardiomyopathy and other cardiovascular conditions. Thus, the increase in healthcare spending and government initiatives focused on heart health are likely to foster growth in the cardiac microcatheter market in the years ahead.

Segmental Analysis

Insights Based on Market Segmentation

The cardiac microcatheter market is categorized into general peripheral vascular and coronary segments. The coronary segment dominated the market share in 2022 and is projected to experience a higher CAGR during the forecast period, driven by the rising prevalence of coronary artery diseases such as angina pectoris and increasing instances of sudden cardiac death.

Insights Based on End Users

In terms of end users, the cardiac microcatheter market is divided into hospitals, specialty clinics, and ambulatory surgical centers. The hospitals segment accounted for the largest market share in 2022 and is expected to register the highest CAGR during the forecast period, fueled by the growing number of hospitals, enhancements in reimbursement policies, and the rising prevalence of cardiovascular diseases.

Key primary and secondary sources utilized in the preparation of this report on the cardiac microcatheter market include the Australian Institute of Health and Welfare and the National Institute of Health, among others.